AKESO INC. O.N. Total Liabilities
AKESO INC. O.N. total liabilities. Based on the latest financial reports, AKESO INC. O.N. (4RY) has total liabilities worth €7.05 Billion EUR (≈ $8.25 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4RY financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of AKESO INC. O.N. (2021–2025)
Total liabilities of AKESO INC. O.N. from 2021 to 2025. This chart illustrates how AKESO INC. O.N.'s total liabilities have evolved over time, based on quarterly financial data.
AKESO INC. O.N. Competitors by Total Liabilities
The table below lists competitors of AKESO INC. O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Service Corporation International
NYSE:SCI
|
USA | $16.99 Billion |
|
Medibank Private Ltd
AU:MPL
|
Australia | AU$1.92 Billion |
|
JSW Energy Limited
NSE:JSWENERGY
|
India | Rs-335.77 Billion |
|
Orkla ASA
OL:ORK
|
Norway | Nkr41.66 Billion |
|
Discovery Holdings Ltd
JSE:DSY
|
South Africa | ZAC261.75 Billion |
|
Knight Transportation Inc
NYSE:KNX
|
USA | $5.01 Billion |
|
Groep Brussel Lambert NV
BR:GBLB
|
Belgium | €11.68 Billion |
|
China Shipbuilding Industry Group Power Co Ltd
SHG:600482
|
China | CN¥64.80 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down AKESO INC. O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AKESO INC. O.N. total assets.
Liquidity & Leverage Metrics
AKESO INC. O.N. Total Liabilities Ratios Explained
AKESO INC. O.N. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AKESO INC. O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AKESO INC. O.N. (2021–2025)
The table below shows the annual total liabilities of AKESO INC. O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.05 Billion ≈ $8.25 Billion |
+17.55% |
| 2024-12-31 | €6.00 Billion ≈ $7.02 Billion |
+28.72% |
| 2023-12-31 | €4.66 Billion ≈ $5.45 Billion |
+58.16% |
| 2022-12-31 | €2.95 Billion ≈ $3.45 Billion |
+93.24% |
| 2021-12-31 | €1.53 Billion ≈ $1.78 Billion |
-- |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more